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Summary 
Three mammalian nuclear lamin proteins, lamin B1, lamin enzymes involved in their farnesylation-dependent 
B2 and the lamin A precursor, prelamin A, undergo maturation. Other experimental work, including mouse 
canonical farnesylation and processing at CAAX motifs. In model studies, have examined the possibility that farnesyl 
the case of prelamin A, there is an additional farnesylation- transferase inhibitors can represent effective treatment for 
dependent endoproteolysis, which is defective in two HGPS. However, there are concerns about their use for this 
congenital diseases: Hutchinson-Gilford progeria (HGPS) purpose given the potential for alternative prenylation 
and restrictive dermopathy (RD). These two diseases arise pathways. 
respectively from defects in the prelamin A substrate and 
the enzyme (ZmpSte24) that processes it. Recent work has 
shed light on the roles of the lamin proteins and the Key words: Farnesylation, Lamins, FTIs, HGPS 
The lamina, lamins and laminopathies 
The lamina is a filamentous protein structure that is proximal to 
the inner nuclear membrane in multicellular eukaryotes. It is 
composed of lamin proteins, which can also be found in the 
nuclear interior, and lamin-associated proteins (Gruenbaum et 
al., 2003). There are two classes of lamin proteins: A-type and 
B-type, which are distinguished by whether they remain 
associated with membrane vesicles (B-type) or not (A-type) 
during mitosis. In mammalian cells there are two common B-
type lamins, lamin B1 and lamin B2, which are encoded by two 
different genes, and two common A-type lamins, lamin A and 
lamin C, which are different mRNA splicing products of the 
same lamin A/C gene. Broadly speaking, the karyoskeleton 
formed by the lamin proteins serves to organize protein 
complexes within the nucleus and their interactions with 
chromatin, as well as providing structural support for the nucleus 
(Gruenbaum et al., 2005; Taddei et al., 2004). In doing so, the 
lamins are involved in a range of nuclear functions, including 
regulation of gene expression and DNA replication, although the 
molecular details of these functions are still to be elucidated. 
Mutations in lamin A produce a range of diseases that have 
collectively been referred to as ‘laminopathies’ (Jacob and 
Garg, 2005). Two progeroid (premature aging) syndromes, 
Hutchinson-Gilford progeria (HGPS) (Cao and Hegele, 2003; 
Eriksson et al., 2003) and restrictive dermopathy (RD) 
(Moulson et al., 2005; Navarro et al., 2005; Navarro et al., 
2004), are laminopathies that arise through defects in 
maturation of the lamin A precursor, prelamin A. 
Mandibuloacral dysplasia (MAD) (Agarwal et al., 2003), 
which can be considered a milder form of RD, also results in 
accumulation of the lamin A precursor. By contrast, the 
majority of laminopathies are due to point mutations in the A/C 
lamins; these exhibit a multitude of phenotypes depending on 
the site of the mutation (Gruenbaum et al., 2003). 
CAAX-boxes, prenylation and the lamin proteins 
The primary translation product of the lamin A mRNA, 
prelamin A, bears a C-terminal CA1A2X motif (Fig. 1) that 
directs farnesylation of the cysteine residue (Zhang and Casey, 
1996) – A1 and A2 are generally aliphatic amino acid residues. 
As described in more detail below, direct chemical methods 
have confirmed farnesylation of prelamin A (Lutz et al., 1992; 
Sinensky et al., 1994), as well as lamin B1 (Farnsworth et al., 
1989), which also terminates in a CAAX motif. 
These studies were among the first to demonstrate 
farnesylation of mammalian proteins. Post-translational 
farnesylation had previously been shown for fungal mating 
pheromones (Kamiya et al., 1980; Miyakawa et al., 1985), and 
the first direct evidence of the relationship between the CAAX 
motif and farnesylation was obtained by NMR (Anderegg et al., 
1988) of the Saccharomyces a-factor. Lamin prenylation was 
first suggested by metabolic labeling with mevalonate 
(mevalonate labeling) and analysis of nuclear proteins by 1- and 
2-dimensional gel electrophoresis (Beck et al., 1988; Beck et al., 
1990; Wolda and Glomset, 1988). Structural verification of 
farnesylation of the lamin proteins was facilitated by earlier 
work on fungi, which implicated the thioether linkage of a 
polyisoprenoid to CAAX-box cysteines as the probable 
structure. This led investigations to use reductive chemical 
cleavage of the thioether linkage with Raney nickel to liberate 
the polyisoprenoid, which could be characterized by GLC-mass­
spectrometry. This approach was first applied to lamin B1 
(Farnsworth et al., 1989). Lamin B1 was an excellent first choice 
for structural determination of the polyisoprenoid because it is 
among the most abundant of the prenylated cellular proteins. 
CAAX boxes and poly-isoprenyl transferases 
The mechanisms by which CAAX boxes direct farnesylation 
are relevant to an understanding of laminopathies. CAAX 











motifs favor farnesylation, by farnesyltransferase (FTase), 
when X is a Ser, Gln, Met or Ala residue but 
geranylgeranylgeranylation, by geranylgeranyltransferase I 
(GGTase-I), when X is a Leu residue (Zhang and Casey, 1996). 
X-ray crystallography (Reid et al., 2004) has recently provided 
a mechanistic basis for the observed specificity of amino acid 
residues at the A2 position and their contribution to the overall 
reactivity of the CAAX-box substrates. These studies indicate 
that the A2 position can influence substrate selectivity by FTase 
and GGTase-I. Therefore, in the case of the lamin proteins, it 
is noteworthy that Ile or Val at the A2 position is equally 
accepted by FTase and GGTase-I. The human lamin CAAX 
boxes are CSIM for prelamin A, CAIM for mammalian lamin 
B1 and CYVM for lamin B2. The preference for lamin 
farnesylation, over geranylgeranylation, thus derives entirely 
from the C-terminal Met residue. Sequences upstream of 
the CAAX box, as well as the A1 residue, 
have the potential to alter the Km for the 
protein substrate but are not mechanistic 
determinants of the specificity of 
prenylation. There are examples in which 
CAAX-motif prenylation occurs when the 
A1 residue is not aliphatic (e.g. Gln in the 
case of Rap-1B and Tyr in the case of lamin 
B2). 
All of the above considerations strongly 
predict that the lamin proteins, including the 
mutant lamin A proteins found in the various 
laminopathies, as well as HGPS, should be 
farnesylated, and further processed at the 
lamin A CSIM motif. As shown in Fig. 1, 
CAAX-box proteins undergo endopeptidase 
cleavage of the – AAX residues (step B) 
after farnesylation followed by 
carboxymethylation (step C) (Zhang and 
Casey, 1996). The B endopeptidase activity 
in step B can be shown for two enzymes: 
Rce1 (Ras-converting enzyme 1) 
(Boyartchuk et al., 1997) and Zmpste24 
(Zinc metalloprotease related to Ste24p) 
(Corrigan et al., 2005; Leung et al., 2001). 
The carboxymethylation is catalyzed by 
the enzyme isoprenylcysteine carboxyl 
methyltransferase (Icmt) (Winter-Vann and 
Casey, 2005). 
Biochemical studies on the 
endoproteolytic maturation of 
prelamin A 
The initial characterization of the processing 
pathway of prelamin A presented some 
challenges. Early work by Gerace and co­
workers (Gerace et al., 1984) had 
demonstrated the likelihood of a higher­
molecular-weight precursor for lamin A. 
Later protein-sequencing studies by Weber 
on the mature lamin A molecule (Weber et 
al., 1989), coupled with comparison to the 
prelamin A sequence predicted from its 
cDNA, demonstrated that lamin A 
undergoes the loss of 18 amino acid residues 
from the C-terminus during the formation of mature lamin A, 
which terminates in a Tyr residue. Metabolic radiolabeling and 
pulse-chase studies with mevalonate demonstrated likely 
prenylation of prelamin A and a requirement for the putative 
prenylation for further maturation of the protein (Beck et al., 
1990). 
The transient nature of prelamin A does not allow 
accumulation of sufficient material for one to characterize the 
putative isoprenoid by mass-spectrometry. Radiolabeling of the 
polyisoprenoid with mevalonate is also difficult because of the 
poor uptake of mevalonate by most cells. The problem of 
obtaining enough radio-labeled material to characterize, was 
eventually solved by the use of inducible prelamin A constructs 
expressed in a cell line with an activated mevalonate 
transporter (Faust and Krieger, 1987). Characterization of the 
prelamin A poly-isoprenoid substituent as farnesyl could then 
Fig. 1. Maturation pathway of prelamin A. Steps A-C are common to all CAAX proteins.
 












proceed through the same Raney-nickel cleavage method that 
had been successfully employed for lamin B1 but utilizing co­
chromatography on GLC with synthetic standards and in-line 
radiodetection to identify the product as being derived from 
farnesyl thioether. 
The inducible prelamin A constructs were utilized to verify 
carboxymethylation of prelamin A (Sinensky et al., 1994). 
Since carboxymethylation can only occur after 
endoproteolysis, this was consistent with prelamin processing 
proceeding through the canonical CAAX-box processing 
pathway (Fig. 1). In vitro studies with recombinant enzymes 
directly demonstrate that both Rce 1 or Zmpste24 can use 
prelamin A as a substrate in step B (Corrigan et al., 2005). 
In vitro studies with a model polypeptide, as well as studies 
on CAAX-box mutants expressed in cells (Kilic et al., 1997), 
showed that a farnesylated, carboxymethylated prelamin A is 
the required substrate for a final endoproteolytic cleavage after 
Tyr646 (step D in Fig. 1) by an enzyme that recognizes a 
conserved hexapeptide cleavage motif RSYfLLG, and gives 
rise to mature lamin A. No other farnesylated mammalian 
protein is known to undergo a second, upstream 
endoproteolysis, and the highly conserved cleavage sequence 
is unique to prelamin A in vertebrate protein sequence 
databases, even allowing for conserved substitutions (Kilic et 
al., 1997). Thus, the second endoproteolysis currently appears 
to be unique to prelamin A processing. 
In vitro studies with recombinant Zmpste24 and a 
recombinant fragment of prelamin A demonstrated that 
Zmpste24 has step D endoprotease activity (Corrigan et al., 
2005). In vivo studies (data not shown) indicate that Zmpste24 
is not essential for the first endoproteolytic cleavage, which can 
also be performed by Rce1, but is essential for the second (our 
unpublished data). 
Genetic studies on farnesylation-dependent lamin 
maturation 
Knockout studies, in fact, first suggested that Zmpste24 is the 
step D endoprotease. As mentioned above, farnesylation was 
first studied in fungal pheromones, particularly Saccharomyces 
a-factor. This polypeptide, like prelamin A, undergoes N-
terminal endoproteolysis during maturation, which is mediated 
by two enzymes: Ste24p and Ste23p. Discovery of a 
mammalian orthologue of Ste24p, Zmpste24, suggested that 
Zmpste24 plays a similar role in prenylation-dependent post-
translational processing in mammalian cells (Young et al., 
2005). Zmpste24-knockout mice (Bergo et al., 2002; Pendas et 
al., 2002) accumulate prelamin A, and the later biochemical 
studies (Corrigan et al., 2005) showed that Zmpste24 can 
mediate both of the endoproteolytic steps in prelamin A 
maturation. 
In mouse embryo fibroblasts lacking Icmt or Rce1 (but not 
those lacking Zmpste24) a fluorescent construct expressing the 
40 C-terminal residues of lamin B1 is mislocalized and the 
nuclear lamina has structural defects (Maske et al., 2003). The 
apparent lack of activity of Zmpste24 in B-lamin processing is 
surprising because the yeast orthologues appear to have 
overlapping substrate specificities (Trueblood et al., 2000). 
Notice, however, that the Rce1 and Icmt knockouts will 
have defective processing of numerous farnesylated and 
geranylgeranylated proteins, which could disrupt lamina 
structure indirectly. 
Farnesylation, prelamin A and progeria 3267 
Prenylated proteins, membranes and farnesylated 
lamins 
Biophysical studies using model farnesylated and 
carboxymethylated peptides indicate that farnesylated proteins 
should be predominantly, but not entirely, membrane 
associated (Silvius and l’Heureux, 1994). The hydrophobic 
contribution of carboxymethylation is also significant and a 
substantial fraction of a protein modified only by a farnesyl 
group would not be expected to be associated with membranes. 
Even with both farnesylation and methylation, the dissociation 
constants of peptides from lipid bilayers can vary from 10 fM 
to several hundred micromolar, depending on the bilayer 
composition. Thus, CAAX-box-mediated association with 
membrane bilayers is inherently reversible. Stable membrane 
association of a farnesylated protein (e.g. Ras) requires a 
second lipid-bilayer-binding moiety (Hancock et al., 1990; 
Schroeder et al., 1997; Shahinian and Silvius, 1995). For Ras 
proteins, this is either palmitoylation (N-Ras and H-Ras) or a 
polybasic domain (K-Ras). Both carboxymethylation and 
palmitoylation are chemically reversible modifications, making 
it theoretically feasible to dissociate even doubly modified 
proteins from membranes. In the case of Ras proteins, both 
palmitoylation status and subcellular localization are highly 
dynamic (Magee and Seabra, 2005). 
This reversibility of membrane association of farnesylated 
proteins is consistent with the hypothesis that CAAX 
modifications, in addition to targeting proteins to membranes, 
also facilitate protein-protein interactions. Indeed, there is 
considerable evidence that this is the case (Basso et al., 2006; 
Sinensky, 2000; Zhang and Casey, 1996). 
Prelamin A mutants that cannot be processed at step D by 
Zmpste24 (Corrigan et al., 2005; Hennekes and Nigg, 1994; 
Mallampalli et al., 2005) are localized to the nuclear 
membrane. Since these mutants are expected to be farnesylated 
and carboxymethylated, these observations support a role for 
these CAAX modifications of prelamin A in nuclear membrane 
targeting (Nigg et al., 1992). Similar observations exist for B­
lamins. Mutations of the lamin B1 (Mical and Monteiro, 1998) 
or lamin B2 (Kitten and Nigg, 1991) CAAX box that block 
prenylation, also block incorporation of the lamin B proteins 
into the nuclear envelope, leading to their accumulation in the 
nucleoplasm. Lamin proteins do not have secondary lipid-
bilayer-binding regions analogous to those of the Ras proteins. 
Membrane association of prenylated lamin proteins might 
therefore be stabilized by their binding to a membrane receptor, 
and a body of evidence supports binding of lamin B1 to a lamin 
B receptor (Smith and Blobel, 1994; Worman et al., 1990; 
Worman et al., 1988). The binding site appears to map to the 
C-terminus of the B-lamins (Dreger et al., 2002; Maske et al., 
2003). 
Since the CAAX-motif modifications of the B-lamins are 
typical of CAAX proteins, their role as mediators of nuclear 
envelope association has a strong rationale. By contrast, the 
functional significance of prelamin A processing, in which the 
farnesylated and carboxymethylated C-terminal peptide is 
ultimately removed, is unknown and intriguing. It is clearly not 
required for assembly of lamin A into the lamina – this has 
been shown by expression studies of the mature protein (Lutz 
et al., 1992) and, of course, mature lamin A is disassembled 
and reassembled into the lamina routinely during the course of 
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that block farnesylation, thereby preventing removal of the C-
terminal 18 residues of prelamin A, block its incorporation into 
the lamina (Holtz et al., 1989; Lutz et al., 1992; Sasseville and 
Raymond, 1995), which suggests that the sequence inhibits 
this. 
One hypothesis is that farnesylated and carboxymethylated 
prelamin A has a distinct function and that the processing 
pathway regulates its levels. In this regard, yeast two-hybrid 
studies have revealed a specific binding partner of farnesylated 
prelamin A: Narf (Barton and Worman, 1999). The function of 
Narf is unknown. However, epitope-tagged Narf localizes to 
both the nuclear envelope and the nucleoplasm, which suggests 
it interacts with farnesylated and carboxymethylated prelamin 
A in both locations. 
RD and HGPS: diseases of prelamin A maturation 
In both RD and HGPS, there is strong circumstantial evidence 
that step D of the prelamin A maturation pathway is defective, 
and we have confirmed this chemically (unpublished data). 
RD (OMIM: 275210) is a neonatally fatal autosomal 
recessive disease that arises from homozygous loss of 
expression of Zmpste24 (Levy et al., 2005; Moulson et al., 
2005; Navarro et al., 2005; Navarro et al., 2004). It is 
characterized by very tight, thin easily eroded skin, rocker-
bottom feet and joint contractures. In addition, prelamin A 
accumulates in cells from RD patients (Moulson et al., 2005; 
Navarro et al., 2005). 
HGPS is a complex autosomal dominant disease (OMIM: 
176660) that arises from a mutation in the prelamin A gene 
that leads to low-level expression of a prelamin A mRNA 
(L150 LMNA) that has a deletion of 150 bp of exon 11 arising 
from a variably used new splice site (Eriksson et al., 2003). 
L150 LMNA constitutes approximately 40% of the transcripts 
found in cells from HGPS patients (Reddel and Weiss, 2004). 
This mutant mRNA encodes a protein (known as LAL50 or 
progerin) that has an in-frame deletion of 50 amino acid 
residues of the prelamin A sequence. Progerin can readily be 
separated from wild-type prelamin A and lamin A on SDS­
PAGE and visualized by anti-lamin-A antibody (Cadinanos et 
al., 2005; Pollex and Hegele, 2004). The predicted amino acid 
sequence of progerin (Eriksson et al., 2003) is missing the 
sequence necessary for step D, RSYfLLG, which is consistent 
with the hypothesis that there is a block in maturation at this 
step (Fig. 2). Progerin, as is the case for artificially generated 
Step-D-resistant mutants, localizes to the nuclear envelope 
(Goldman et al., 2004). 
Patients with HGPS exhibit physical features reminiscent of 
aging, including bone fragility, loss of hair and lipodystrophy 
(Pollex and Hegele, 2004). They also have extensive vascular 
problems, which lead to premature atherosclerosis and stroke, 
common causes of death (Gordon et al., 2005; Ha et al., 1993; 
McClintock et al., 2006). Cells from HGPS patients senesce 
prematurely in culture (Liu et al., 2005; Wallis et al., 2004). 
This appears to arise from DNA-repair defects, which results 
in accumulation of DNA double-strand breaks and p53 
activation (Liu et al., 2005). Similar events are associated with 
senescence of cultured human cells and cells from aging mice 
(Sedelnikova et al., 2004). HGPS may thus, at least in some 
respects, reflect normal aging. Indeed, it has recently been 
reported (Scaffidi and Misteli, 2006) that progerin accumulates 
in tissues from aged individuals. 
Fig. 2. (A,B) Expected C-terminal fragments of (A) wild-type 
prelamin A and (B) progerin after trypsin digestion. Relative 
molecular masses were calculated using average masses of the 
occurring residues and giving masses as [M+H]+. 
Homozygous loss of Zmpste24 in RD should also result in 
the generation of a farnesylated and carboxymethylated 
prelamin A, Rce1 performing the first endoproteolysis. No 
wild-type lamin A is produced in this case (Toth et al., 2005). 
A compound-heterozygous loss-of-function of Zmpste24 
(OMIM: 608612) causes mandibuloacral dysplasia 
characterized by ‘skeletal abnormalities including hypoplasia of 
the mandible and clavicles, acro-osteolysis, cutaneous atrophy 
and lipodystrophy’ (Agarwal et al., 2003). This condition might 
reflect incomplete loss of Zmpste24, because the neonate is 
viable. Mouse embryo fibroblasts from Zmpste24–/– mice show 
the same molecular and cellular characteristics of premature 
senescence similar to those seen in patients with HGPS (Liu et 
al., 2005; Varela et al., 2005). Farnesylated, carboxymethylated 
prelamin is associated with the nuclear membrane, including 
invaginations of this membrane into the nucleus (Holtz et al., 
1989; Moulson et al., 2005; Toth et al., 2005). By contrast, non­
prenylated CAAX-box cysteine mutants of prelamin A 
accumulate in nucleoplasmic aggregates (Capell et al., 2005; 
Holtz et al., 1989; Lutz et al., 1992), which are not membrane 
associated (Fig. 3). 
Farnesyl transferase inhibitors, lamin maturation 
and HGPS 
Shortly after lamin proteins were shown to be farnesylated, the 
mammalian Ras proteins were shown to be similarly modified 
(Casey et al., 1989; Leonard et al., 1990). A body of yeast 
genetic studies (Goodman et al., 1990; Powers et al., 1986; 
Schafer et al., 1990) had previously suggested that post-
translational modification of Ras was required for its signaling 
and subsequent work showed Ras farnesylation is required for 
the transforming activity of oncogenic Ras mutants (Casey et 
al., 1989; Hancock et al., 1989; Schafer et al., 1989). This 
raised the possibility that inhibitors of farnesyl transferase 
(FTIs) could be used in the treatment of cancer. A number of 
such compounds were developed, and their current status has 
recently been reviewed (Basso et al., 2006). Surprisingly, 
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Fig. 3. (A-C) Subnuclear distribution of wild-
type and mutant prelamin A. (A) Wild-type 
EGFP-prelamin A, (B) prenylation­
incompetent mutant prelamin A (661CrM) 
and, (C) step-D-incompetent prelamin­
A–EGFP–progerin were transiently expressed 
in HeLa cells and imaged live (A,C) or after 
indirect immunofluorescence with anti­
prelamin A antibodies (B). Digital images 
taken by light-microscopy and digital 
deconvolution are shown. 
prenylation, maturation and function of H-Ras are inhibited by 
the FTIs, this is not the case for N-Ras and K-Ras (Fiordalisi 
et al., 2003; James et al., 1996; Rowell et al., 1997; Whyte et 
al., 1997). The explanation is that they become 
geranylgeranylated in the presence of FTIs. This is because of 
the kinetic basis of specificity towards CAAX substrates of 
FTase and GGTase1. In the case of K-Ras, there is an ~400­
fold higher Km for K-Ras for GGTase 1 compared with FTase 
(Roskoski, Jr and Ritchie, 1998; Zhang et al., 1997). However, 
the kcat values for the two enzymes for K-Ras are virtually 
identical. Thus, at high cellular levels of non-prenylated K-Ras, 
as would be the case when farnesylation is blocked, 
geranylgeranylation by GGTase1 can occur (James et al., 
1995). By contrast, GGTase1 exhibits not only a higher Km for 
H-Ras than does FTase but the kcat is >100 times lower, which 
accounts for the effectiveness of FTIs in blocking H-Ras 
prenylation. Signaling, including oncogenic signaling, by 
mutant K-Ras (Kato et al., 1992), and by implication N-Ras, 
can be supported by geranylgeranylation. 
These observations should sound a cautionary note on how 
biological readouts can be overinterpreted in explanations of 
biochemical events. FTIs can, indeed, block the growth of 
numerous N-Ras- and K-Ras-transformed cells in soft agar, 
nude mice or transgenic mouse models (End et al., 2001; Liu 
et al., 1999; Nagasu et al., 1995; Omer et al., 2000). They just 
do not necessarily do it by affecting the prenylation of the Ras 
proteins. Other farnesylated proteins have been implicated in 
the antitumor activity of FTIs (Basso et al., 2006) 
FTIs have also been proposed as a treatment for HGPS. RD 
is not a candidate for treatment since it is neonatally lethal. The 
rationale for such an approach is that the pathological 
phenotypes seen in HGPS arise from a farnesylated, mutant 
prelamin A and that inhibition of its farnesylation might 
reverse these phenotypes. Encouragingly, the blebs that have 
been observed in the nuclear membranes of cultured fibroblasts 
from patients with HGPS can be eliminated by treatment with 
FTIs (Capell et al., 2005; Glynn and Glover, 2005; Mallampalli 
et al., 2005; Toth et al., 2005). Although, at this time, no direct 
demonstration of the farnesylation of progerin has been 
reported, mevalonate labeling studies by one laboratory (Glynn 
and Glover, 2005) are certainly consistent with this prediction. 
The loss of mevalonate labeling of progerin upon treatment of 
HGPS cells with an FTI is also consistent with inhibition of 
farnesylation but can be misleading (see below). 
FTI treatment has been shown to ameliorate the pathology 
exhibited by Zmpste24–/– mice (Fong et al., 2006) although the 
responses vary depending on the defect. For example, the 
effects of treatment on the mice are very dramatic in the case 
of reduction of rib fractures but less so in the case of growth 
(as measured by body weight). Although there are structural 
differences between progerin and the prelamin A molecule that 
accumumulates in the absence of Zmpste24, there are 
obviously shared structural features, especially the farnesylated 
and carboxymethylated C-terminal cysteine residue. Thus, 
these results are consistent with the concept that FTIs could be 
useful in the treatment of HGPS. 
Examining the effects of the FTI BZA-5B, on prelamin A 
maturation (Dalton et al., 1995) in CHO-K1 cells expressing 
an activated mevalonate transporter, we observed specific 
inhibition of protein farnesylation. Considering one recent 
database search revealed ~70 potential farnesylated proteins 
(Fiordalisi et al., 2003), it was surprising that growth of CHO­
K1 and HeLa cells is not inhibited by treatment with BZA-5B. 
Although prelamin A accumulates, its processing still occurs, 
as does assembly of lamin A and lamin B into the nuclear 
lamina. Farnesylation-dependent protein processing appears to 
occur even in the absence of detectable farnesylation. The lack 
of mevalonate labeling of N-Ras, lamin B1 or prelamin A in 
these cells in the presence of BZA-5B was not consistent with 
processing by alternative prenylation. Other work, however, 
has suggested that mevalonate labeling of geranylgeranylated 
CAAX proteins can be difficult to detect (Kato et al., 1992; 
Vestal et al., 1996). Furthermore, in vitro studies on the 
prenylation of lamin A and lamin B CAAX polypeptides 
(Moores et al., 1991) demonstrate that both can be a substrate 
for GGTase 1, as do studies of in vitro translated prelamin A 
mRNA (our unpublished data). Expression of prelamin A 
containing a CVLL geranylgeranylation CAAX box in 
mammalian cells results in a geranylgeranylated protein that is 
processed to mature lamin A, albeit inefficiently, such that 
prelamin A accumulates (Kilic et al., 1997). 
FTI treatment could result in inefficient processing of 
prelamin A at two steps. Since the Km of GGTase 1 for the 
prelamin A CAAX of should be considerably higher than 
that of FTase, non-prenylated prelamin A should accumulate; 
since the Km of Zmpste24 for the geranylgeranylated 
prelamin A is higher than for farnesylated prelamin A, the 
geranylgeranylated precursor might accumulate as well. 
Prelamin A has been detected with specific anti-prelamin-A 
antibody in patients treated with FTIs (Adjei, 2003), but the 
prenylation status of the accumulated protein was not 
determined. 
Thus, those investigating treatment of HGPS with FTIs face 
the same questions that concern investigators developing them 
for treatment of malignancy. (1) Given the spectrum of 
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protein of interest specifically? (2) Can alternative prenylation 
produce sufficient levels of biologically active prenylated 
protein to result in inadequate reversal of the pathological 
phenotype? As in the case of the Ras proteins, these issues are 
exacerbated by the desirability of blocking farnesylation of the 
mutant protein but not the wild-type. 
Possible methods for characterization of progerin in 
cells treated with FTIs 
Could progerin become a substrate for GGTase 1 in the 
presence of an FTI? This seems quite possible and it certainly 
should be tested if these compounds are to be considered for 
use in the treatment of HGPS. In our hands, characterization 
of progerin by mass spectrometry does not give information 
on the putative farnesylated and carboxymethylated C-
terminal cysteine residue. Since this is generally done after 
trypsin digestion of the sample protein, the peptide fragment 
expected from progerin is larger than that produced from 
normal human prelamin A (Fig. 2) (Corrigan et al., 2005). 
The reasons it has not been detected are not immediately 
obvious. 
Alternative methods for analysis of the polyisoprenoid 
substituents include labeling of the polyisoprenoids with 
mevalonate followed by radiochemical analysis of the cleavage 
product (Dalton and Sinensky, 1995). As mentioned above, 
labeling of prenylated proteins with mevalonate is greatly 
facilitated by using cell lines that express an activated 
mevalonate transporter (Faust and Krieger, 1987; Whyte et 
al., 1997) and incubating cells with lovastatin to block 
endogenous mevalonate biosynthesis. High-specific activity 
[3H]mevalonate is incorporated into proteins either as farnesyl 
or geranylgeranyl substituents. These can be released by 
cleavage of the thioether linkage by either Raney nickel to yield 
the corresponding alkenes or methyl iodide to yield the 
corresponding alcohols (Casey et al., 1989). The alkenes are 
best resolved by GLC; the alcohols are best resolved by 
reverse-phase HPLC. The latter has the advantage of not 
requiring in-line radiodetection if this apparatus is not 
available. Specific labeling of farnesylated proteins can also be 
achieved with tritiated farnesol (Andres et al., 1999). 
Another useful method, which gives an indirect 
measurement of the extent of prenylation but not the 
polyisoprenoid specificity, is a base-release assay of the 
prenylated protein after labeling of the lamin protein with 
[tritiated CH3]-methionine. This method has been successfully 
applied to the lamin proteins (Chelsky et al., 1987; Dalton and 
Sinensky, 1995). Typically, the results are normalized with 
respect to the total incorporation of the methionine into protein 
relative to the number of methionines, and compared with 
lamin B1 for a theoretical 100% CAAX-modification. This 
methodology should also be useful for evaluation of alternative 
processing because a true block to prenylation would also 
block carboxymethylation. 
A recent novel approach to determining farnesylation has 
been described by Spielmann, Andres and colleagues 
(Troutman et al., 2005). They grow cells in medium 
supplemented with the farnesol analogue anilinogeraniol. This 
compound incorporates into proteins in place of farnesol, and 
its incorporation can be measured by antibodies directed 
against S-anilinogeranyl cysteine methyl ester. This technique 
is particularly directed at demonstrating the action of an FTI, 
because the signal would disappear upon FTI treatment. It 
would not, however, detect alternative prenylation because 
that would not be distinguishable from the absence of 
prenylation. However, it could be combined with another 
method that tests for whether prenylation occurs in the 
presence of the FTI. 
Conclusions and perspectives 
To the cell biologist, the most interesting aspect of the lamin 
CAAX-box post-translational modifications is their functional 
significance. As pointed out above, these modifications 
generally seem to function to create reversible membrane 
associations and heterodimeric protein-protein interactions. 
The B-lamins appear to represent examples of this common 
behavior of farnesylated proteins. 
The functional role of the CAAX-box modification of 
prelamin A is, by contrast, quite puzzling, because it is 
eliminated during the course of prelamin A maturation and thus 
unique among mammalian CAAX proteins. In the dominant 
progeroid syndrome, HGPS, prelamin A accumulates to only 
very low levels and wild-type lamin A levels are not 
dramatically affected. Prelamin A itself may thus have a 
functional role and Zmpste24 could serve to regulate its levels. 
That cellular senescence accompanies accumulation of 
farnesylated prelamin A in HGPS and RD may provide a clue 
to that function. 
These considerations should stimulate further investigation 
into the role of farnesylation in the function of prelamin A. The 
idea that inhibition of prelamin A farnesylation is a potential 
therapeutic approach, warrants further biochemical analysis of 
the effects of FTIs on post-translational modification not only 
of progerin but also of prelamin A and the B-lamins. 
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